[Current aspects of antirheumatic therapy in pregnancy planning, during pregnancy and breastfeeding].

Häfeli, Celine; Förger, Frauke (2021). [Current aspects of antirheumatic therapy in pregnancy planning, during pregnancy and breastfeeding]. Zeitschrift für Rheumatologie, 80(8), pp. 716-725. Springer-Medizin-Verlag 10.1007/s00393-021-01095-z

Preview

Text FFOE1.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (350kB) | Preview

Active rheumatic disease is a known factor for increased fetomaternal risks during pregnancy. Remission or inactive disease should therefore be targeted to reduce these risks by using pregnancy-compatible antirheumatic drugs as recommended by international guidelines. Teratogenic antirheumatic drugs, such as mycophenolate, methotrexate, cyclophosphamide and thalidomide should be stopped about 3 months prior to conception. Leflunomide is a weak human teratogen that should be stopped and eliminated with cholestyramine prior to conception. Furthermore, drugs with limited data, such as apremilast and JAK inhibitors as well as new biologics should be avoided during gestation. Pregnancy-compatible drugs are the antirheumatic drugs hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, tacrolimus, colchicine, non-selective NSAIDs, low-dose prednisone/prednisolone and TNF inhibitors. These drugs as well as other biologics, such as rituximab can be used during lactation. In a preconception counselling visit, the benefits and the international recommendations of pregnancy-compatible antirheumatic drugs should be discussed with the patient and be weighed against the possible fetomaternal risks of an active disease to enable a shared decision-making.

Interest & Impact

Downloads

112 since deposited on 03 Dec 2021
59 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item